Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the cost utility of a pilot study of Korean Lung Cancer Screening Project. Materials and methods: We constructed a Markov model consisting of 26 states based on the natural history of lung cancer according to the Surveillance, Epidemiology, and End Results summary stage (localized, regional, distant). In the base case, people aged 55-74 years were under consideration for annual screening. Costs and quality-adjusted life years were simulated to calculate the incremental cost utility ratio. Sensitivity analyses were performed on the uncertainty associated with screening target ages, stage distribution, cost, utility, mortality, screening duration, and discount rate. Results: The base case (US$25,383 per quality-adjusted life year gained) was cost-effective compared to the scenario of no screening and acceptable considering a willingness-to-pay threshold of US$27,000 per quality-adjusted life years gained. In terms of the target age of screening, the age between 60 and 74 years was the most cost-effective. Lung cancer screening was still cost-effective in the sensitivity analyses on the cost for treatment, utility, mortality, screening duration, and less than 5% discount rates, although the result was sensitive to a rise in positive rates or variation of stage distribution. Conclusion: Our results showed the cost-effectiveness of annual low-dose computed tomography screening for lung cancer in high-risk populations.
Abstract
Purpose: The aim of this study was to evaluate the cost utility of a pilot study of Korean Lung Cancer Screening Project. Materials and methods: We constructed a Markov model consisting of 26 states based on the natural history of lung cancer according to the Surveillance, Epidemiology, and End Results summary stage (localized, regional, distant). In the base case, people aged 55-74 years were under consideration for annual screening. Costs and quality-adjusted life years were simulated to calculate the incremental cost utility ratio. Sensitivity analyses were performed on the uncertainty associated with screening target ages, stage distribution, cost, utility, mortality, screening duration, and discount rate. Results: The base case (US$25,383 per quality-adjusted life year gained) was cost-effective compared to the scenario of no screening and acceptable considering a willingness-to-pay threshold of US$27,000 per quality-adjusted life years gained. In terms of the target age of screening, the age between 60 and 74 years was the most cost-effective. Lung cancer screening was still cost-effective in the sensitivity analyses on the cost for treatment, utility, mortality, screening duration, and less than 5% discount rates, although the result was sensitive to a rise in positive rates or variation of stage distribution. Conclusion: Our results showed the cost-effectiveness of annual low-dose computed tomography screening for lung cancer in high-risk populations.
참고문헌 (43)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2019", Cancer Research and Treatment, 51(2), pp.431~437 (2019), 대한암학회
- "Daily smokers" (2021)[URL]
- Kang MH, "TheNational Cancer Screening Program for breast cancer in theRepublic of Korea : is it cost-effective?", Asian Pac J Cancer Prev, 14, pp.2059~2065 (2013)
- Cho E, "Cost-effectiveness of Korea’s National Cervical Cancer ScreeningProgram", Asian Pac J Cancer Prev, 14, pp.4329~4334 (2013)
- 박상민, "대장암 선별검사의 비용 - 효과분석", Korean Journal of Family Medicine, 25(4), pp.297~306 (2004), 대한가정의학회
- Cho E, "Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea", Asian Pac J Cancer Prev, 14, pp.2533~2540 (2013)
- Yun EH, "Trends in participation rates of the National Cancer Screening Program among cancer survivors in Korea", Cancers(Basel), 13, pp.81~ (2020)
- National Lung Screening Trial Research Team, "Reducedlung-cancer mortality with low-dose computed tomographicscreening", N Engl J Med, 365, pp.395~409 (2011)
- Black WC, "Cost-effectiveness of CT screening in the National LungScreening Trial", N Engl J Med, 371, pp.1793~1802 (2014)
- de Koning HJ, "Reduced lung-cancermortality with volume CT screening in a randomized trial", N Engl J Med, 382, pp.503~513 (2020)
- Du Y, "Cost-effectiveness of lung cancerscreening with low-dose computed tomography in heavysmokers : a microsimulation modelling study", Eur J Cancer, 135, pp.121~129 (2020)
- Griffin E, "Lung cancer screening by low-dose computedtomography : a cost-effectiveness analysis of alternative programmes in the UK using a newly developed natural history-based economic model", Diagn Progn Res, 4, pp.20~ (2020)
- Jaine R, "Cost-effectivenessof a low-dose computed tomography screening programmefor lung cancer in New Zealand", Lung Cancer, 144, pp.99~106 (2020)
- Lee J, "Feasibility of implementing a national lung cancer screening program : Interim results from the Korean Lung Cancer Screening Project(K-LUCAS)", Transl Lung Cancer Res, 10, pp.723~736 (2021)
- 이재호, "Development of Protocol for Korean Lung Cancer Screening Project (K-LUCAS) to Evaluate Effectiveness and Feasibility to Implement National Cancer Screening Program", Cancer Research and Treatment, 51(4), pp.1285~1294 (2019), 대한암학회
- SEERsummary staging manual - 2000: codes and coding instructions, "Young JL", National Cancer Institute, ~, pp.Report No. NIH Pub. No. 01-4969 (2001)
- Mahadevia PJ, "Lung cancer screening with helical computedtomography in older adult smokers : a decision and cost-effectiveness analysis", JAMA, 289, pp.313~322 (2003)
- "National cancer registration program" (2020)[URL]
- Fleurence RL, "Rates and probabilities in economic modelling : transformation, translation and appropriate application", Pharmacoeconomics, 25, pp.3~6 (2007)
- "Complete life table" (2020)[URL]
- Gellert C, "Smoking and all-causemortality in older people : systematic review and meta-analysis", Arch Intern Med, 172, pp.837~844 (2012)
- Kim DD, "Perspective and costing in cost-effectiveness analysis, 1974-2018", Pharmacoeconomics, 38, pp.1135~1145 (2020)
- Health Insurance Review and Assessment Service, "Guidelines for economic evaluation of pharmaceuticals in Korea", Health Insurance Review and Assessment Service, ~ (2011)
- Survey on the benefit coverage rate of National Health Insurance in 2006, "Kim JH", National Health Insurance, ~, pp.Report No.2007-01 (2008)
- Areport of Korea health panel survey 2008 (1), "Jung YH", Korea Institute for Health and Social Affairs, ~, pp.Report No. 2009-28 (2009)
- Cost estimation methods in the healthcare sector, "Lee T", National Evidence-based Healthcare CollaboratingAgency, ~ (2011)
- "2015 currencyexchange rate" (2020)[URL]
- "Survey data" (2016)[URL]
- Kim EJ, "Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea", BMC Cancer, 18, pp.1081~ (2018)
- Walters S, "Comparability of stage data in cancer registries in six countries : lessons from the International Cancer Benchmarking Partnership", Int J Cancer, 132, pp.676~685 (2013)
- Goldstraw P, "The IASLC Lung Cancer Staging Project : proposals for revision of the TNM stage groupings inthe forthcoming(eighth)edition of the TNM classification for lung cancer", J Thorac Oncol, 11, pp.39~51 (2016)
- Research on methodologies for evidence-based healthcare decision-making processin Asia, "Ahn JH", National Evidence-Based Collaborating Agency, ~ (2012)
- Raymakers AJ, "Cost-effectiveness analyses of lung cancer screening strategies using low-dose computed tomography : a systematic review", Appl Health Econ Health Policy, 14, pp.409~418 (2016)
- Song HJ, "Evaluation of willingness to pay per quality-adjusted life year for a cure : a contingent valuation methodusing a scenario-based survey", Medicine(Baltimore), 97, pp.e12453~ (2018)
- "Lung cancer survival rates" (2021)[URL]
- Wu FZ, "Prognostic effect of implementation of the mass low-dosecomputed tomography lung cancer screening program : a hospital-based cohort study", Eur J Cancer Prev, 29, pp.445~451 (2020)
- Cataldo JK, "Smoking cessation : an integral part of lung cancer treatment", Oncology, 78, pp.289~301 (2010)
- Goffin JR, "Cost-effectiveness of lung cancer screening in Canada", JAMA Oncol, 1, pp.807~813 (2015)
- Villanti AC, "A cost-utilityanalysis of lung cancer screening and the additional benefitsof incorporating smoking cessation interventions", PLoS One, 8, pp.e71379~ (2013)
- Kim EY, "Adherence to general medical checkup and cancer screening guidelinesaccording to self-reported smoking status : Korea NationalHealth and Nutrition Examination Survey(KNHANES)2010-2012", PLoS One, 14, pp.e0224224~ (2019)
- "Cancer incidence" (2021)[URL]